Initial low dose presents early efficacy signals Second cohort now fully dosed at twice the initial dose Further results to be disclosed in Q1 2024 VICTORIA, BC – Eupraxia Pharmaceuticals… Read More
Older adults who incur falls are increasingly becoming prone to spinal cord injuries as a result—and research suggests a combination of working or being independent longer and age-related degeneration may… Read More
Health research teams across British Columbia are putting knowledge into action with funding awarded by Michael Smith Health Research BC. The Convening & Collaborating (C2) and Reach funding programs are… Read More
Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023… Read More
Vancouver, BC – WEX Pharmaceuticals Inc., a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has commenced its Quantitative Sensory Testing (QST) clinical trial and is… Read More
